{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:29:22Z","timestamp":1778599762430,"version":"3.51.4"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T00:00:00Z","timestamp":1309910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0021930","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T20:56:42Z","timestamp":1309985802000},"page":"e21930","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Small Compound 6-O-Angeloylplenolin Induces Mitotic Arrest and Exhibits Therapeutic Potentials in Multiple Myeloma"],"prefix":"10.1371","volume":"6","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-Xing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Xian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Biao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,7,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple Myeloma.","volume":"351","author":"RA Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma.","volume":"374","author":"MS Raab","year":"2009","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002.","volume":"55","author":"DM Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"M Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"PG Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"M Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor Activity of Thalidomide in Refractory Multiple Myeloma.","volume":"341","author":"S Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccr.2004.10.020","article-title":"Focus on multiple myeloma.","volume":"6","author":"CS Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma.","volume":"20","author":"T Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1034\/j.1600-065X.2003.00065.x","article-title":"Cell-cycle control of plasma cell differentiation and tumorigenesis.","volume":"194","author":"S Chen-Kiang","year":"2003","journal-title":"Immunol Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-065X.2003.00052.x","article-title":"Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.","volume":"194","author":"PL Bergsagel","year":"2003","journal-title":"Immunol Rev"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"11345","DOI":"10.1158\/0008-5472.CAN-05-2159","article-title":"Mutually exclusive cyclin-dependent kinase 4\/cyclin D1 and cyclin-dependent kinase 6\/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.","volume":"65","author":"S Ely","year":"2005","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1600-065X.2003.00054.x","article-title":"Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.","volume":"194","author":"JD Shaughnessy Jr","year":"2003","journal-title":"Immunol Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2004-07-2721","article-title":"High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma.","volume":"105","author":"E Bjorck","year":"2005","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.1570","article-title":"Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination.","volume":"97","author":"H Lin","year":"2002","journal-title":"Int J Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model.","volume":"68","author":"E Menu","year":"2008","journal-title":"Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs.","volume":"4","author":"MA Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neulet.2006.06.074","article-title":"Okadaic acid induced cyclin B1 expression and mitotic catastrophe in rat cortex.","volume":"406","author":"B Chen","year":"2006","journal-title":"Neuroscience Letters"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(03)01321-4","article-title":"Cell-cycle targeted therapies.","volume":"5","author":"C Swanton","year":"2004","journal-title":"The Lancet Oncology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF02977470","article-title":"Inhibitory activity of 6-O-angeloylprenolin from Centipeda minima on farnesyl protein transferase.","volume":"29","author":"HM Oh","year":"2006","journal-title":"Arch Pharm Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0031-9422(97)00534-7","article-title":"Antibacterial constituents of the Nepalese medicinal herb, Centipeda minima.","volume":"47","author":"RS Taylor","year":"1998","journal-title":"Phytochemistry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-2006-957833","article-title":"Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata.","volume":"62","author":"G Francois","year":"1996","journal-title":"Planta Med"},{"key":"ref23","first-page":"675","article-title":"Antimalarial activity of plant metabolites.","volume":"19","author":"S Schwikkard","year":"2002","journal-title":"Nat Prod Rep"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/10286020903029231","article-title":"Two new terpene glucosides and antitumor agents from Centipeda minima.","volume":"11","author":"LF Ding","year":"2009","journal-title":"J Asian Nat Prod Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.biopha.2007.10.010","article-title":"6-O-Angeloylenolin induces apoptosis through a mitochondrial\/caspase and NF-[kappa]B pathway in human leukemia HL60 cells.","volume":"62","author":"L ChangLong","year":"2007","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"ref26","first-page":"335","article-title":"Characterization of a novel myeloma cell line, MM.1.","volume":"113","author":"RE Goldman-Leikin","year":"1989","journal-title":"J Lab Clin Med"},{"key":"ref27","first-page":"477","article-title":"Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.","volume":"7","author":"K Nilsson","year":"1970","journal-title":"Clin Exp Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas.","volume":"332","author":"M Kawano","year":"1988","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1158\/0008-5472.CAN-05-0850","article-title":"FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.","volume":"65","author":"H Yasui","year":"2005","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-06-032250","article-title":"Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.","volume":"109","author":"GB Zhou","year":"2007","journal-title":"Blood"},{"key":"ref31","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.","volume":"62","author":"R LeBlanc","year":"2002","journal-title":"Cancer Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00432-008-0416-0","article-title":"MZ3 can induce G2\/M-phase arrest and apoptosis in human leukemia cells.","volume":"134","author":"L Fang","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/MCB.22.3.874-885.2002","article-title":"Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases.","volume":"22","author":"C Crosio","year":"2002","journal-title":"Mol Cell Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1128\/MCB.15.7.3463","article-title":"Different roles for cyclins D1 and E in regulation of the G1-to-S transition.","volume":"15","author":"D Resnitzky","year":"1995","journal-title":"Mol Cell Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1471-2407-6-292","article-title":"Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.","volume":"6","author":"O Hashimoto","year":"2006","journal-title":"BMC Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/10049","article-title":"Temporal and spatial control of cyclin B1 destruction in metaphase.","volume":"1","author":"P Clute","year":"1999","journal-title":"Nat Cell Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semcdb.2005.02.007","article-title":"New insights into cyclins, CDKs, and cell cycle control.","volume":"16","author":"I Sanchez","year":"2005","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"ref38","first-page":"211","article-title":"Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).","volume":"11","author":"X Grana","year":"1995","journal-title":"Oncogene"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm2163","article-title":"The spindle-assembly checkpoint in space and time.","volume":"8","author":"A Musacchio","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2005.06.011","article-title":"Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.","volume":"8","author":"BA Weaver","year":"2005","journal-title":"Cancer Cell"},{"key":"ref41","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.","volume":"61","author":"T Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.","volume":"352","author":"PG Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"ref43","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.","volume":"118","author":"A Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.","volume":"103","author":"S Chu","year":"2004","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","article-title":"Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.","volume":"109","author":"O Piloto","year":"2007","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications.","volume":"104","author":"T Hideshima","year":"2004","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.","volume":"5","author":"CS Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications.","volume":"21","author":"CS Mitsiades","year":"2002","journal-title":"Oncogene"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.","volume":"10","author":"R Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1541-7786.MCR-09-0565","article-title":"Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products.","volume":"8","author":"KB Harikumar","year":"2010","journal-title":"Mol Cancer Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a Therapeutic Target in Multiple Myeloma.","volume":"277","author":"T Hideshima","year":"2002","journal-title":"J Biol Chem"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2007.08.021","article-title":"Molecular understanding and modern application of traditional medicines: triumphs and trials.","volume":"130","author":"TW Corson","year":"2007","journal-title":"Cell"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0163-7258(84)90025-1","article-title":"Taxol: an antimitotic agent with a new mechanism of action.","volume":"25","author":"JJ Manfredi","year":"1984","journal-title":"Pharmacol Ther"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1097-0320(19980101)31:1<53::AID-CYTO7>3.0.CO;2-K","article-title":"Characterization of cyclin B1 expression in human cancer cell lines by a new three-parameter BrdUrd\/cyclin B1\/DNA analysis.","volume":"31","author":"M Faretta","year":"1998","journal-title":"Cytometry"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.canlet.2005.09.013","article-title":"Quercetin arrests G2\/M phase and induces caspase-dependent cell death in U937 cells.","volume":"240","author":"TJ Lee","year":"2006","journal-title":"Cancer Lett"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/ncb1436","article-title":"Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology.","volume":"8","author":"DS Kirkpatrick","year":"2006","journal-title":"Nat Cell Biol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1158\/0008-5472.CAN-08-3133","article-title":"A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor.","volume":"69","author":"JH DeMoe","year":"2009","journal-title":"Cancer Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/1535-7163.MCT-06-0319","article-title":"Spindle checkpoint function and cellular sensitivity to antimitotic drugs.","volume":"5","author":"HY Yamada","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1097-2765(00)80126-4","article-title":"Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1.","volume":"2","author":"G Fang","year":"1998","journal-title":"Mol Cell"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.","volume":"87","author":"D Chauhan","year":"1996","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-{kappa}B activation in multiple myeloma cells.","volume":"114","author":"T Hideshima","year":"2009","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0021930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T05:18:17Z","timestamp":1592716697000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0021930"}},"subtitle":[],"editor":[{"given":"Micah","family":"Luftig","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,7,6]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0021930","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,6]]}}}